Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Stock data | 2023 | Change |
---|---|---|
Price | $0.4595 | N/A |
Market Cap | $943.69K | N/A |
Shares Outstanding | 2.05M | 39.17% |
Employees | 15.00 | N/A |
Shareholder Equity | 15.06M | -11.34% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.08 | N/A |
P/S Ratio | 1.64 | N/A |
P/B Ratio | 0.06 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.7986 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $574.25K | N/A |
Earnings | -$12.03M | N/A |
EPS | -5.90 | N/A |
Earnings Yield | -12.84 | N/A |
Operating Margin | -20.72 | N/A |
Net income margin | -20.95 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $17.51M | N/A |
Total Debt | $1.21M | N/A |
Cash on Hand | $14.53M | N/A |
Debt to Equity | 0.1623 | 13.64% |
Cash to Debt | $12.02 | -48.64% |
Current Ratio | $10.03 | 0.72% |